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Abstract
Introduction The prevalence of liver steatosis is par-
ticularly high in subjects with signs of the metabolic syn-
drome, and current therapeutic guidelines mostly rely on
lifestyle changes alone, which rarely achieve significant
objective improvements. In the present study, we evaluated
the possibility of monitoring objective improvements in
these subjects, before and after a dietary regimen.
Methods Overall, 78 subjects with metabolic syndrome
and ultrasound confirmation of liver steatosis were included
in an open, controlled study; all of these subjects were treated
for 90 days with the standard regimen of diet and exercise.
One group of 43 subjects (Group A) also received a Eurosil
85-based nutraceutical (silymarin ? vitamin E) as a di-
etary adjunct, whereas the remaining 35 subjects (Group B)
represented the control group. Changes from baseline values
were recorded in biometric, biochemical, and ultrasound
data. For assessments and monitoring of liver steatosis, two
indexes were utilised—Hepatic Steatosis Index (HSI) and
Lipid Accumulation Product (LAP) index.
Results The absolute changes from baseline were sig-
nificantly higher in Group A in biometric parameters (re-
duction of abdominal circumference, Body Mass Index,
ultrasound measurement of right liver lobe) and in both the
HSI and LAP indexes. Both treatments were well tolerated.
Conclusion The results observed suggest that the use of a
Eurosil 85-based nutraceutical as a dietary adjunct with
antioxidant properties potentially favours the efficacy of the
dietary regimen alone and may possibly improve the
subjects’ motivation to sustain such lifestyle changes
over time.
1 Introduction
Non-alcoholic fatty liver disease (NAFLD), a condition
ranging from uncomplicated liver steatosis to steatohep-
atitis (NASH) and potentially to end-stage diseases such as
cirrhosis or hepatocarcinoma [1], is the most common
cause of liver disease worldwide [2, 3]. The prevalence of
liver steatosis in Italy has been reported to be within the
35–40 % range in the general population [4–6], with sharp
increases in overweight and obese subjects (67 and 91 %,
respectively [7]). Whereas the concomitant presence of
liver steatosis, obesity and insulin resistance is a common
clinical finding, there is still ongoing research to elucidate
the pathogenetic mechanisms involved [8, 9]; for example,
whether NAFLD is a cause or consequence of insulin re-
sistance [10]. However, accumulating evidence confirms
not only a correlation between NAFLD and the metabolic
syndrome [8, 11, 12] but also the association of NAFLD
with an increased cardiovascular risk [13]. Intrahepatic
oxidative stress is also known to be one of the critical
factors that may determine progression of NAFLD to more
severe conditions involving liver inflammation and fibrosis
[12]. Therefore, from the standpoint of the primary care
physician, monitoring the presence of liver steatosis in
subjects with signs of metabolic syndrome (particularly
abdominal obesity, elevated triglycerides and abnormal
fasting glycaemia) should be normal clinical practice, with
the aim of taking preventive measures against the devel-
opment of more severe stages of NAFLD. Since the usual
biochemical parameters (alanine transaminase [ALT],
aspartate transaminase [AST], c-glutamyl transpeptidase
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[cGT]) may be within normal ranges in patients with un-
complicated steatosis, their use as a screening test would
probably result in underestimation of the presence of
NAFLD, whereas imaging techniques such as liver ultra-
sonography (USG) are a potentially more sensitive tool for
diagnosis of liver steatosis [3, 14]. According to recent
guidelines [3], the therapeutic approach to liver steatosis is
mostly focused on lifestyle interventions, including weight
reduction, dietary modification and aerobic physical exer-
cise [3]. A weight loss of at least 7 % has been shown to
improve steatosis and also to reduce parameters of
necroinflammation [15]. However, actual long-term com-
pliance of subjects with NAFLD to lifestyle intervention
protocols is usually reported to be unsatisfactory. Rein-
forcing the ‘motivation to change’ in these subjects seems
to be a critical factor, and strategies of targeted behavioural
counselling, to provide these subjects not only with moti-
vation but also with tools to monitor improvements and
therefore to sustain the lifestyle changes, have been pro-
posed for evaluation in clinical trials [16]. In a similar
perspective, with the aim of improving the subjective and
objective results of lifestyle changes in subjects with liver
steatosis, and therefore to possibly reinforce their motiva-
tion to compliance, the present study has observed the ef-
fects of a nutraceutical product as an adjunct to the
standard diet and exercise regimen. Since silymarin has
consistently been shown to improve parameters related to
insulin resistance [17–20], we have observed the efficacy
and tolerability of a nutraceutical based on a new formu-
lation of silymarin which provides, at the recommended
daily posology, a high dosage of the active ingredient
silibinin, together with vitamin E. The clinical use of oral
formulations containing silymarin or silibinin has been
documented in several clinical trials conducted in patients
with ASH or NASH [17–20]. Vitamin E, when used at a
high dosage (800 IU), has also been shown to improve
several inflammatory parameters in patients with NASH
[21]. The specific aim of the present study was to observe
whether, in subjects with a less advanced stage of NAFLD
(steatosis), a moderate regimen of diet and exercise, plus a
combination of a relatively low dosage of vitamin E
(60 IU) and a new formulation of silymarin (by its an-
tioxidant activities) could provide additional clinical
improvements.
2 Methods
2.1 Patients and Clinical Assessments
From September to December 2013, a total of 80 con-
secutive subjects in generally good health, who had visited
their primary care doctor for digestive disturbances and had
been referred to our Echography Service in order to per-
form USG to determine the presence and stage of liver
steatosis and to measure the size of the right liver lobe [21,
22], were proposed to be included in an open, controlled,
observational clinical study. The study design was quite
simple. All subjects with at least grade 1 steatosis and
concomitant presence of metabolic syndrome were pre-
scribed a standard Mediterranean diet to follow for
3 months, since good efficacy has been reported with this
kind of diet in NAFLD patients [23]; in particular, 1 month
of a fibre-rich, moderately ipocaloric diet with preferential
use of food with medium or low glycaemic index, followed
by 2 months of an isocaloric diet with similar food balance.
In addition, subjects were encouraged to take regular
physical exercise (e.g. 15 min of brisk walking/day). A
subgroup of subjects, with matching biometric parameters
and physical conditions, was also prescribed to take, as a
dietary adjunct, two tablets/day of a nutraceutical product
containing (in each tablet) 210 mg of Eurosil 85, a new
silymarin formulation with approximately 60 % (e.g.
125 mg) of silibinin and 30 IU of vitamin E (Legalon E,
Rottapharm Madaus, Monza, Italy). To ensure compliance,
all patients of the latter group were immediately given a
supply of 200 tablets of nutraceutical product (sufficient for
the treatment period). All subjects were also given a leaflet
where the initial slightly ipocaloric diet and the subsequent
maintenance diet were clearly detailed. They were also
scheduled for a control visit and re-assessment of all bio-
metric, biochemical parameters and USG tests after
90 days. The inclusion criteria were confirmation of liver
steatosis (at least grade 1), abdominal circumference
[94 cm in men or [80 cm in women, triglyceride levels
(TGL) [150 mg/dL (1.7 mmol/L), and fasting glycaemia
[100 mg/dL (5.6 mmol/L). Exclusion criteria were
ongoing acute or chronic hepatitis, presence of other
diagnosed liver diseases, signs of biliary obstruction, daily
alcohol intake [30 mg, concomitant use of antioxidant
products such as silymarin, ademethionine and glutathione,
uncontrolled diabetes mellitus and/or major change in an-
tidiabetic therapy within the previous 3 months. These
conditions were ruled out at screening visit by anamnesis,
physical examination and routine laboratory analyses.
Body Mass Index (BMI), abdominal circumference, blood
pressure, glycaemia, glycated haemoglobin, triglyceride
and cholesterol (total, low-density lipoprotein, high-density
lipoportein) levels, ALT, AST, and cGT were recorded,
together with the standard anamnestic data, as baseline
values for all patients. The Hepatic Steatosis Index (HSI)
and the Lipid Accumulation Product (LAP) index were
also calculated, as these are simple tools for the assessment
of liver steatosis. The HSI was calculated using the formula
[(8 9 ALT/AST) ? BMI (?2 if female) (?2 if with dia-
betes mellitus)], and the LAP was calculated using the
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formula [abdominal circumference in cm (-65 if male or
-58 if female) 9 TGL in mmol/L] [24, 25].
2.2 Ultrasonography
All subjects were examined by the same doctor, in order to
minimise individual variability, by means of an Aplio di-
agnostic ultrasound system (Toshiba Medical Systems,
Tokyo, Japan) with convex multifrequency probe/trans-
ducer 3–5 MHz. Ascending oblique subcostal scans of the
right lobe were performed; for the left lobe, longitudinal
scans were taken (during inspiratory apnea) at the point in
which the cava vein connects to the right atrium. The usual
assessment (grades 0–3) of steatosis was adopted, where
grade 0 represents normal echogenicity, non-different from
renal cortex echogenicity with homogeneous texture and
therefore no steatosis; grade 1 occurs when the liver
echogenicity is minimally increased with reference to the
renal cortex, with slightly rougher texture; grade 2 occurs
when the liver echogenicity reduces deeper ultrasound
projection and clear distinctions of portal vein branches;
and grade 3 occurs when the marked increase in liver
echogenicity, with non-homogenous texture, obscures the
vascular walls and diaphragmatic outline. A lateral left
position, in inspiratory apnea, was then adopted to assess
the liver size; ascending subcostal longitudinal scans were
performed [22].
2.3 Statistics
Continuous variables were assessed by means of mixed
adjusted models by the baseline measure as a covariate.
Differences were also assessed using a t test for the main
outcomes. Categorical variables were compared using
Fisher’s exact test. The analysis was performed using SAS
9.2 software (SAS Institute Inc., Cary, NC, USA) and the
level of significance was established at 0.05 (two-sided).
3 Results
Results are shown in Table 1 (as means of the absolute
changes from respective baselines); the statistical differ-
ences are shown between the changes observed in Group A
(subjects treated with the nutraceutical as an adjunct to
diet) and in the control group (Group B; treatment with diet
only). Baseline values of the two groups were not sig-
nificantly different. BMI and abdominal circumference did
not change in Group B, whereas a significant reduction
(p = 0.022 and p = 0028, respectively) was found in
Group A. In the latter group the average USG-measured
size of the right liver lobe decreased from baseline
(17.24 cm) to the final visit at 90 days (-0.96 cm), while
in Group B the decrease was smaller (-0.41 cm), with
significant difference (p = 0.044) between groups. ALT
and AST values were within the normal limit at baseline;
even if no differences between the two groups were found
in their changes from baseline, the calculation of HSI
(which includes BMI and the presence of diabetes mellitus)
highlighted a significant difference in reduction in Group A
(p = 0.0134). Similarly, even if the reduction in triglyc-
eride level showed only a higher reduction trend in Group
A, using the calculation of the LAP index (which also
considers the abdominal circumference), a significant
(p \ 0.001) difference is achieved. No adverse events have
been reported.
4 Discussion
The role of dietary intervention in the management of
NAFLD is well-established and the so-called ‘lifestyle
change’ approach still represents, in the absence of other
conditions, the basic recommendation for subjects with
liver steatosis [3]. However, published evidence, in ac-
cordance with usual clinical practice, reports that the effi-
cacy of this approach is often diminished by poor
implementation and reduced adherence to the prescribed
regimen of diet and exercise [16]. The results of the present
3-month observational study, conducted with non-diabetic
subjects diagnosed with liver steatosis and also
characterised by the presence of insulin resistance and
other signs of metabolic syndrome, confirm that lifestyle
intervention alone may not be sufficient to achieve sig-
nificant objective improvements which may be important
to favour the necessary long-term adherence to such a
regimen. In subjects with similar clinical features, it has
recently been reported that significant improvements in
Bright Liver Score are achieved only after 6 months of
adherence to a Mediterranean diet together with regular
physical exercise [26]. For these reasons, the significantly
improved results that we have observed in the parallel
group (in which subjects were instructed not only to follow
the dietary regimen but also to assume a dietary adjunct
with a specific liver antioxidant rationale), may represent
an example of a more integrated approach that could
achieve clinical improvements within a shorter timeframe
(3 months) and possibly motivate a sustained adherence to
the lifestyle change. Since transaminases are usually within
normal limits, we feel that the use of an AST/ALT ratio
and validated derived indexes such as fatty liver index, HIS
and LAP may be helpful in assessing the severity of the
liver steatosis, thereby representing an additional simple
and non-expensive diagnostic tool. Recent studies have
found that when compared with gold-standard methods for
the detection and quantification of liver fat content
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(e.g. liver biopsy and proton magnetic resonance spec-
troscopy), the steatosis biomarkers are not comparatively
reliable to quantify liver steatosis, particularly in the
presence of fibrosis and inflammation [27, 28]. However, in
subjects with relatively mild symptoms, when the use of
invasive or expensive clinical tests are not usually recom-
mended, the surrogate biomarkers may still be helpful in
monitoring the efficacy of lifestyle changes and possible
adjunct treatments. In this study, the choice of the silymarin-
based nutraceutical has been based on the documented
safety, even at a high dosage [29], and the scientific evi-
dence of the pharmacokinetic and pharmacologic proper-
ties of silymarin. Once absorbed from the gastrointestinal
tract, silibinin (the main component of silymarin) under-
goes liver metabolisation. Due to enterohepatic cycling
[29], it subsequently concentrates in the liver where it may
exert the antioxidant properties that have been extensively
documented both in vitro and in vivo [30, 31], and the
improvement in parameters of insulin resistance that have
also been documented [17–19]. On the other hand, the role
of insulin resistance and intrahepatic oxidative stress in the
pathogenesis of NAFLD and in the progression of disease
severity has been repeatedly highlighted [10, 12]. At
the recommended posology of two capsules/day, the
nutraceutical provides 420 mg of Eurosil 85, a silymarin
preparation containing 60 % (e.g. approximately 250 mg)
of silibinin and 60 IU of vitamin E.
Our study has several limitations: the relatively small
numerosity, the trend towards higher biometric parameters
that we found in the group treated with both diet and a
nutraceutical, and the difficulty in confirming compliance
to the prescribed diet and exercise regimen. Moreover, the
USG assessments have not been performed by a ‘blind’
third party, and the decrease in the HSI and LAP indexes
that we have observed in the 3-month period are still
relatively small. However, with regard to the USG
assessments, all have been performed by a single investi-
gator, who took maximal care in following a well-stan-
dardised procedure. With regard to the small effect size,
this was sufficient to provide the treating primary care
doctors with some objective evidence by which they could
more effectively encourage subjects to continue the
treatments.
5 Conclusion
The present non-interventional study suggests that, in
subjects with liver steatosis and metabolic syndrome, who
are prescribed a recommended diet and exercise regimen to
Table 1 Demographic, biometric, ultrasonographic, biochemical data
(mean ± SD), as well as Hepatic Steatosis Index (HSI) and Lipid
Accumulation Product (LAP) index, measured at baseline and after
90 days of treatment with a nutraceutical as an adjunct to diet (Group
A) or with diet-only (Group B)
Group A Group B Change from baseline
Baseline 90 days Baseline 90 days Group A Group B Statistical
difference
between groups
N 43 43 35 35
Age (years) 56.63 ± 12.79 55.40 ± 13.63
Gender (M/F) 18/25 18/25 24/11 24/11
BMI 31.8 ± 4.80 31.1 ± 4.85 29.7 ± 3.66 29.7 ± 3.79 -0.71 -0.004 p = 0.022
Abdominal circumference 109.3 ± 11.6 104.53 ± 11.18 104.5 ± 8.9 102.74 ± 9.00 -4.81 -1.78 p = 0.028
Right liver lobe (cm) 17.24 ± 2.11 16.28 ± 2.22 16.64 ± 1.42 16.23 ± 1.70 -0.96 -0.41 p = 0.044
Fasting plasma glucose
(mg/dL)
109.74 ± 25.35 115.75 ± 28.19 106.62 ± 28.70 107.11 ± 15.42 6.01 0.49 NS
Hb A1c % 4.36 ± 2.18 4.62 ± 0.73 4.38 ± 2.22 4.89 ± 1.07 0.26 0.51 p \ 0.05
ALT (IU/L) 33.08 ± 26.97 28.02 ± 22.27 25.11 ± 15.56 24.76 ± 14.59 -5.06 0.35 NS
AST (IU/L) 23.78 ± 14.40 22.49 ± 12.45 20.13 ± 6.18 21.37 ± 11.29 -1.29 1.24 NS
cGt (IU/L) 43.83 ± 52.27 33.33 ± 21.59 27.98 ± 14.14 28.60 ± 14.66 -10.50 0.62 NS
Triglycerides (mg/dL) 182.33 ± 90.68 133.11 ± 67.24 156.09 ± 61.65 137.01 ± 63.26 -49.22 -19.08 NS
Total cholesterol (mg/dL) 216.78 ± 52.80 205.98 ± 45.67 209.27 ± 39.59 208.55 ± 31.37 -10.8 -0.73 NS
LDL-C (mg/dL) 117.37 ± 34.09 113.58 ± 28.39 117.82 ± 29.54 118.38 ± 29.62 -3.79 0.56 NS
HDL-C (mg/dL) 57.25 ± 18.78 56.22 ± 12.48 55.67 ± 14.92 57.63 ± 15.27 -1.02 2.00 NS
HSI 43.62 ± 5.49 41.76 ± 5.59 40.20 ± 5.23 40.00 ± 5.41 -1.85 -0.19 p = 0.0134
LAP 97.77 ± 48.50 64.06 ± 33.03 75.43 ± 40.89 62.28 ± 33.94 -33.72 -13.16 p \ 0.001
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follow, the use of a nutraceutical with specific antioxidant
properties as a dietary adjunct may improve the efficacy of
those lifestyle changes. We suggest the need for a larger,
randomised clinical trial to provide further insight into the
current evidence.
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